Biotech entity
pharma is the sole category represented across all 1 tracked stories. Infant Botulism is most often covered alongside CDC, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Infant Botulism, all published on June 15, 2026.
Last mentioned: Jun 15, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Infant Botulism is most often covered alongside CDC, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Infant Botulism, all published on June 15, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Infant Botulism. Shared-story counts are live from our verified record — not editorial picks.
A cluster of three infant botulism cases, despite zero positive C. botulinum tests in product lots, has forced Nara Organics to recall all whole milk powdered formula. The incident raises critical quality control and sterility challenges for the organic infant nutrition sector.
Source: newson6.com · cbsnews.com
Infant Botulism is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
